Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

82.75GBp
9:08am BST
Change (% chg)

-0.30 (-0.36%)
Prev Close
83.05
Open
84.50
Day's High
84.50
Day's Low
81.70
Volume
28,163
Avg. Vol
1,109,808
52-wk High
90.15
52-wk Low
65.85

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.78
Market Cap(Mil.): £553.37
Shares Outstanding(Mil.): 666.30
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 32.51 37.25
EPS (TTM): -0.13 -- --
ROI: -14.73 12.52 12.15
ROE: -16.44 13.83 16.99

Drugmaker Vectura parts ways with CEO Ward-Lilley

British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

10 Jun 2019

UPDATE 1-Drugmaker Vectura parts ways with CEO Ward-Lilley

June 10 British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

10 Jun 2019

Drugmaker Vectura CEO James Ward-Lilley to step down

June 10 British drugmaker Vectura Group Plc's chief executive officer, James Ward-Lilley, will step down by the end of this month, the company said on Monday.

10 Jun 2019

BRIEF-Vectura Group To Receive $2.5 Mln Milestone Payment For QVM149 Submission

* WILL RECEIVE A $2.5MILLION MILESTONE PAYMENT UNDER AN EXCLUSIVE LICENCE AGREEMENT WITH NOVARTIS AG Source text for Eikon: Further company coverage:

24 May 2019

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

04 May 2019

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

04 May 2019

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

03 Jan 2019

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

03 Jan 2019

UPDATE 3-Vectura hopes new respiratory device will breathe life into business

* Forecasts 2018 adjusted core earnings above market forecasts

03 Jan 2019

UK drugmaker Vectura expects 2018 earnings to top market forecasts

Jan 3 British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.

03 Jan 2019

Earnings vs. Estimates